Understand the source comparison
Best Peptides for Female Sexual Health: Mechanism Comparison
PT-141 (Bremelanotide) Melanocortin-4 receptor agonist Hypothalamus (dopamine pathways) 45–60 minutes subcutaneous FDA-approved; Phase 3 RCTs in 1,267 women Strongest evidence for generalized low libido in premenopausal women; works independent of hormone leve
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (Bremelanotide)
- Melanocortin-4 receptor agonist
- Hypothalamus (dopamine pathways)
- 45–60 minutes subcutaneous
- FDA-approved; Phase 3 RCTs in 1,267 women
- Strongest evidence for generalized low libido in premenopausal women; works independent of hormone levels
- Kisspeptin-10
- Kisspeptin receptor (KISS1R) agonist
- GnRH neurons, limbic system
- 20–30 minutes IV; subcutaneous data pending
- Phase 2 trials; fMRI evidence in healthy volunteers
- Most promising for context-dependent arousal enhancement; delivery route remains a barrier
- Oxytocin (intranasal)
- Oxytocin receptor agonist
- Amygdala, nucleus accumbens
- 20–40 minutes intranasal
- Small pilot studies; mechanism well-established
- Best adjunct for performance anxiety and orgasmic dysfunction; not a standalone libido enhancer
- Melanotan II
- Broad melanocortin receptor agonist
- MC1R, MC4R (hypothalamus)
- 30–60 minutes
- Off-label use; no Phase 3 data in women
- PT-141's parent compound; higher side effect burden (tanning, nausea); no advantage over PT-141